By ThinkSabio #ThinkSabio Latest News
Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting
Subscribe
for ThinkSabio Updates !
We'll keep you up to date about our Stocks, Sec Alerts , Trendings Stocks etc..